| Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status. | |
| | |
MedLine Citation:
|
PMID: 23299279 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: Cytoreductive nephrectomy (CN) plays an important role in the multimodal treatment of metastatic renal cell carcinoma (RCC). However, certain patients experience rapid progression of the carcinoma following CN. This study aimed to investigate the value of neutrophil-to-lymphocyte ratio (NLR) in the selection of patients for CN. METHODS: Records corresponding to 73 patients with metastatic RCC were retrospectively reviewed. Forty-eight patients underwent CN, and their overall survival (OS) and preoperative variables were analyzed. The OS of patients who did not undergo CN was used as a reference. RESULTS: Univariate analysis showed that symptomatic tumors, Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≥1, hemoglobin level <12 g/dl, neutrophil count ≥5500/μL, C-reactive protein level ≥2.0 mg/dl, and NLR ≥4.0 were significantly associated with poor outcomes in patients who underwent cytoreductive nephrectomy. The median OS of patients with NLR ≥4.0 was 10.2 months, which was significantly shorter than that of patients with NLR <4.0 (36.5 months) (P = 0.0020). Multivariate analysis showed that NLR and ECOG-PS were independent predictors of OS in patients treated with CN. The OS of CN patients with NLR ≥4.0 and ECOG-PS ≥1 was similar to that of patients who did not undergo CN (8.4 vs. 6.1 months, P = 0.939). CONCLUSIONS: Preoperative NLR elevation is significantly associated with poor outcomes in patients with metastatic RCC who underwent CN. Patients with NLR ≥4.0 and ECOG-PS ≥1 might not benefit from immediate CN after initial diagnosis. |
| | |
Authors:
|
Yoshio Ohno; Jun Nakashima; Makoto Ohori; Ayako Tanaka; Takeshi Hashimoto; Tatsuo Gondo; Tadashi Hatano; Masaaki Tachibana |
Related Documents
:
|
23417759 - Efficacy and safety of deferasirox in myelodysplastic syndromes. 22955029 - State of intracortical inhibitory interneuron activity in patients with chronic stroke. 23661909 - A comparison of cognitive functions in non-hypoxemic chronic obstructive pulmonary dise... 23504279 - Volume changes in soft tissue sarcomas during preoperative radiotherapy of extremities ... 23364469 - Spinal cord neurosarcoidosis. 23312969 - Surgical and neurologic outcomes after robotic thymectomy in 100 consecutive patients w... 7775959 - Follow-up of antibody responses to human papillomavirus type 16 e7 in patients treated ... 8212999 - Phase ii study of recombinant human granulocyte-macrophage colony-stimulating factor in... 23417759 - Efficacy and safety of deferasirox in myelodysplastic syndromes. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-9 |
Journal Detail:
|
Title: International journal of clinical oncology Volume: - ISSN: 1437-7772 ISO Abbreviation: Int. J. Clin. Oncol. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9616295 Medline TA: Int J Clin Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Urology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 1600023, Japan, yoshio-o@tokyo-med.ac.jp. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patient...
Next Document: Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma ...